1. A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy.

    European Journal of Cardio-thoracic Surgery 48(2):196 (2015) PMID 25342849

    The occurrence of bronchopleural fistula (BPF) after pneumonectomy is associated with high morbidity and mortality. The incidence of BPF in historical patients not subjected to bronchial stump coverage (BSC) was between 6 and 12% after pneumonectomy for lung cancer surgery or benign disease. BSC...
  2. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.

    The Lancet Oncology 16(5):561 (2015) PMID 25882986

    Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian cancer. We did this...
  3. Adjuvant ovarian suppression in premenopausal breast cancer.

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901438

  4. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

    Journal of Clinical Oncology 33(8):910 (2015) PMID 25624439

    Information about symptomatic toxicities of anticancer treatments is not based on direct report by patients, but rather on reports by clinicians in trials. Given the potential for under-reporting, our aim was to compare reporting by patients and physicians of six toxicities (anorexia, nausea, vo...
  5. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

    Journal of Clinical Oncology 33(8):910 (2015) PMID 25624439

    Information about symptomatic toxicities of anticancer treatments is not based on direct report by patients, but rather on reports by clinicians in trials. Given the potential for under-reporting, our aim was to compare reporting by patients and physicians of six toxicities (anorexia, nausea, vo...
  6. [Looking for sustainability of new anticancer drugs].

    Recenti progressi in medicina 106(1):11 (2015) PMID 25621773

    Economic problems have been reported ever more frequently to affect the chance of cancer treatment, and financial toxicity has become a relevant issue in many countries, including the United States. Data are lacking for Europe, but the impressive cost of all new anticancer drugs is challenging E...
  7. What is the future for cancer clinical trials?

    Future Oncology 11(1):5 (2015) PMID 25572779

  8. [Looking for sustainability of new anticancer drugs].

    Recenti progressi in medicina 106(1):11 (2015) PMID 25621773

    Economic problems have been reported ever more frequently to affect the chance of cancer treatment, and financial toxicity has become a relevant issue in many countries, including the United States. Data are lacking for Europe, but the impressive cost of all new anticancer drugs is challenging E...
  9. What is the future for cancer clinical trials?

    Future Oncology 11(1):5 (2015) PMID 25572779

  10. [Looking for sustainability of new anticancer drugs].

    Recenti progressi in medicina 106(1):11 (2015) PMID 25621773

    Economic problems have been reported ever more frequently to affect the chance of cancer treatment, and financial toxicity has become a relevant issue in many countries, including the United States. Data are lacking for Europe, but the impressive cost of all new anticancer drugs is challenging E...
  11. What is the future for cancer clinical trials?

    Future Oncology 11(1):5 (2015) PMID 25572779

  12. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

    The Lancet Oncology 15(12):1379 (2014) PMID 25439692

    Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. In this double-blind, ran...
  13. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

    The Lancet Oncology 15(12):1379 (2014) PMID 25439692

    Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this dis...
  14. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

    The Lancet Oncology 15(12):1379 (2014) PMID 25439692

    Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. In this double-blind, ran...
  15. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

    The Lancet Oncology 15(12):1379 (2014) PMID 25439692

    Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. In this double-blind, ran...
  16. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

    The Lancet Oncology 15(11):1254 (2014) PMID 25232001

    Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer. However, the optimum number of treatment cycles remains controversial. Therefore, we did a systematic review and meta-analysis of individual patient data to compare the efficac...
  17. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

    The Lancet Oncology 15(11):1254 (2014) PMID 25232001

    Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer. However, the optimum number of treatment cycles remains controversial. Therefore, we did a systematic review and meta-analysis of individual patient data to compare the efficac...
  18. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

    The Lancet Oncology 15(11):1254 (2014) PMID 25232001

    Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer. However, the optimum number of treatment cycles remains controversial. Therefore, we did a systematic review and meta-analysis of individual patient data to compare the efficac...
  19. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

    The Lancet Oncology 15(11):1254 (2014) PMID 25232001

    Background Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer. However, the optimum number of treatment cycles remains controversial. Therefore, we did a systematic review and meta-analysis of individual pati...
  20. Treatment of small cell lung cancer.

    Critical Reviews in Oncology/Hematology 91(3):257 (2014) PMID 24767978

    Treatment of small cell lung cancer (SCLC) remains a significant challenge for the oncologists. Attempts to improve the results of first-line treatment have all failed so far and no real progress has been made in last years, emphasizing the need for novel strategies of treatment and the developm...